

Auxesis Pharma Holding AB (publ)

Org.nr: 559195-6486

Cap Table & Investment Opportunity

The Opportunity

Auxesis Pharma develops the **Pain Block™ platform** - a proprietary technology for fast, non-systemic local pain relief and treatment of skin irritation. The first product, **ASA.P®**, is an over-the-counter topical gel designed for rapid relief of pain and skin irritation, built on a well-established active substance (ASA).

- One platform technology enabling multiple brands: Pharmaceuticals (ASA.P®, Opirexa™, Derivexa™, CoxyPet®) and Dermatology (Cutivelle™, Lenvée™)
- Focus on high-value pain management and medical skincare niches, OTC and Rx
- Phased route to market: Nordics as reference market first, followed by the rest of EU and North America

Why Invest Now

- Clear clinical and regulatory pathway, in partnership with CTC Uppsala and RegSmart Life Science
- Strong IP strategy: 2 PCT patent applications and trademark protection in 45 countries
- Capital-efficient, platform-based development model with multiple brands from one technology
- Multiple partnering / licensing exit routes and a planned IPO

Solid ägarstruktur / Ownership Structure

Shareholder	Ownership	Notes
Grundare med bolag	58,4%	Privately and via companies. Founder and business developer within the Auxesis Group since 2015.
Övriga aktieägare / Other shareholders	41,6%	Mainly private individuals and smaller companies.

Auxesis has approximately 800 shareholders. Source for shareholdings: Euroclear Sweden, which maintains the share register. Figures as of 2026-06-30.

Financing Strategy

Current round	Series A
Target round size	Up to SEK 40M, offering 20% equity, 24 months runway
Ongoing tranche	Up to SEK 24.6M (400,000 new shares × SEK 82)
Latest valuation	SEK 651–708 million
Funding to date	More than SEK 80 million invested to date

Use of Funds

- 20% Clinical development – advance clinical trials, regulatory activities and market approval
- 20% Product development – strengthen pipeline and formulation development
- 15% Business development – strategic partnerships, manufacturing and supply chain
- 15% Working capital – organizational growth, key hires and corporate operations
- 15% IP & regulatory – expand patent protection and international registrations
- 15% Commercial readiness – prepare for market access and launch execution

Target Outcome

- Value inflection via clinical milestones and proof-of-concept data
- Strategic licensing or M&A optionality
- Pathway toward a specialty pharma commercial model, with a planned IPO

Investment Highlights

- Large global pain relief, dermatology and cosmeceuticals market (USD 250–350Bn combined)
- Strong differentiation vs. existing systemic pain treatments
- Platform potential across pharmaceuticals, veterinary medicine and dermatology
- Experienced management, board and scientific advisory network

Pain Block™ Investment Story

The Problem

Local skin pain and irritation are common, yet most available treatments rely on systemic medication that affects the whole body, has a slower onset of action, and carries a higher risk of side effects – particularly for children.

The Solution

Auxesis Pharma has developed a proprietary technology platform for local, non-systemic treatment of skin pain and irritation. The stabilized active ingredient penetrates the skin locally, blocks pain signals at the source, and does not enter the bloodstream.

- Novel local pharmacology applied to topical pain relief
- Designed for insect bites, sun rash, nettle stings, minor skin irritation and post-aesthetic treatment recovery
- Nordics as reference market, with a phased roll-out to the rest of EU and North America

Platform Potential

- Indication expansion across pain management, dermatology and veterinary medicine
- Lifecycle management through new formulations and additional brands

Business Model

- Platform-centric specialty pharma model – one technology, multiple brands
- Value creation through clinical de-risking and IP expansion
- Monetization via B2B sales, regional distributors, licensing and strategic partners

Market Opportunity

- OTC skin & pain relief market: USD 12.2Bn globally by 2027, 5.2% CAGR
- Europe and North America represent 68% of global demand
- Pharmaceuticals, dermatology and cosmeceuticals markets combined: USD 250–350Bn globally

Competitive Advantage

- Pharmacology-driven local pain relief vs. traditional systemic treatments
- Strong IP strategy around formulation and use, with international patent applications pending
- Capital-efficient, platform-based development path across multiple brands
- Experienced leadership team with a combined track record of over US\$50M raised and successful exits (M&As, IPOs)

Exit Pathways

- Strategic licensing after clinical value inflection
- Acquisition by a specialty pharma, pain relief or dermatology leader
- Planned IPO, with a multi-brand platform build-out optionality

The Vision

Build a global specialty pharma company around the Pain Block™ platform, improving quality of life for people living with local skin pain and skin disorders.

Contact

Auxesis Pharma Holding AB (publ)

Org.nr: 559195-6486

Email: auxesis@auxesispharma.com

Website: www.auxesis.se

Confidential – For Investor Discussion Only. This document is illustrative and based on current assumptions and the latest available pitch material (5 Aug 2026). Actual outcomes may differ materially.